International Myeloma Foundation

02/09/2026

You don’t have to face myeloma alone. The IMF has support groups for you, local and online, so you can connect with people who understand, ask questions, and get through the tough days together. Find a group near you at support.myeloma.org

02/08/2026

“Remission vs cure?” IMF Chief Medical Officer Dr. Joseph Mikhael answers your myeloma questions.
Have a question? Comment below.

02/07/2026

Life-saving treatments for multiple myeloma exist, including CAR T-cell therapy and bispecific antibodies. Yet new research shows that many patients and care partners are still unfamiliar with these options, and community doctors face practical barriers and limited access to these options outside academic centers.

This award-winning study aimed to answer this important question: Who knows about these breakthrough therapies, and what obstacles stand in the way of reaching them?

What the research found:

The study found that a significant number of people living with myeloma have limited awareness of CAR T-cell therapies, with knowledge gaps more common among Black Americans.
Community physicians face challenges including long distances to treatment centers, transportation needs, and complicated referral pathways that can slow access to specialized care.

Why this matters:

Breakthrough treatments can only help when people know about them and are connected to centers that provide them. The study highlights that education, coordination between community and academic teams, and strong support systems are just as important as developing new medicines.

Why this matters during Black History Month:

Multiple myeloma is 2x as common among Black Americans, yet they remain underrepresented in research participation and experience greater gaps in awareness about advanced therapies. Recognizing and addressing these inequities is essential to ensuring that these innovations benefit everyone.

How the IMF is shaping the future of myeloma care:

This research was led by Abena Prempeh, an IMF Medical Student Scholar for Health Equity in Myeloma, with mentorship from Dr. Manisha Bhutani, and earned a prestigious ASH Abstract Achievement Award. Through this program, the IMF is arming a new generation of health professionals with knowledge to close gaps in care, improve representation in research, and strengthen pathways to treatment for all patients.

Learn more about this award-winning research and the IMF Medical Student Scholars for Health Equity in Myeloma program here: https://mmsm.link/49BRrUS

02/06/2026

Do you have more questions about ? We host seminars, workshops, and online webinars throughout the year to help you learn and get support. Visit events.myeloma.org to get connected.

02/06/2026

African Americans make up ~14% of the U.S. population but account for nearly 20% of myeloma diagnoses. This higher risk makes awareness and access to care critical. The IMF is committed to changing the course of myeloma in the African American community so people can live well and live long. Learn more: https://mpower.myeloma.org

02/05/2026

Myeloma care shouldn’t depend on where you live or what language you speak. The IMF is working to expand education, support, and research in more languages and culturally responsive ways so everyone can access early detection, trials, and new therapies.

02/05/2026

“Can I still lift heavy at the gym?” IMF Chief Medical Officer Dr. Joseph Mikhael answers your questions. Have a question? Comment below.

02/04/2026

“Any alternatives to dexamethasone?” IMF Chief Medical Officer Dr. Joseph Mikhael answers your questions. Have a question? Comment below.

02/04/2026

: Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and for FREE on March 28, 2026! Will we see you there? Save your seat before spots are gone: https://mmsm.link/3Ns8Dox

The International Myeloma Foundation (IMF) advances science and research to improve the lives of myeloma patients while working toward prevention and a cure.

02/04/2026

World Cancer Day is a powerful reminder to unite and take action against cancer. The IMF stands alongside our myeloma advocates to drive change and improve access to care. Join us in advocating for a better future: https://advocacy.myeloma.org

02/04/2026

A new myeloma treatment designed for hard-to-treat disease has just been fast-tracked by the FDA. For people living with high-risk relapsed or refractory multiple myeloma, treatment options can become limited over time. Many of these patients reach a point where they have already received several therapies and still need new choices.

There is new progress to share.

The U.S. Food and Drug Administration has granted Fast Track Designation to IBI3003, an investigational trispecific antibody being studied for people with relapsed or refractory multiple myeloma who have already received multiple prior treatments.

Unlike a bispecific antibody, which attaches to a single receptor on the myeloma cell, trispecific IBI3003 is designed to target two myeloma cell receptors, BCMA and GPRC5D. This approach is meant to help the immune system better recognize and attack myeloma cells, even in those whose disease has returned or stopped responding to other therapies.

Early results were shared at the 2025 American Society of Hematology meeting. The study included people with hard-to-treat “high-risk” disease, including extramedullary myeloma (when myeloma grows outside the bone) and those previously treated with similar immune-based therapies.

Why this matters:

FDA Fast Track Designation helps speed the development and review of treatments for serious conditions with unmet needs. For people living with advanced myeloma, this means promising therapies may move through the clinical trial process more quickly and reach patients sooner if proven safe and effective.

IBI3003 is still being studied and is not yet approved. Clinical trials are ongoing internationally, with a U.S. study expected to begin soon.
Learn more: https://mmsm.link/3ZCKQoB

At the International Myeloma Foundation, we are committed to helping people living with myeloma and their families understand the changing myeloma landscape. Call us, we’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call 1-818-487-7455 or email infoline@myeloma.org

02/03/2026

Support groups change everything. Adrienne and Chad know this firsthand. After Adrienne's myeloma diagnosis, they found strength in connection and now lead an IMF support group in Illinois to bring education, community, and hope to others. No one should face myeloma alone. There’s a support group for you. Find one near you or join online at support.myeloma.org.